Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-04T21:34:50.553Z Has data issue: false hasContentIssue false
  • English
  • Français

Persistent neuroleptic – related hypersonmia: two case reports

Published online by Cambridge University Press:  13 June 2014

Riadh T Abed  and
D Bhalla
Riadh T Abed
Affiliation:
University of Sheffield, Rotherham District General Hospital, Moorgate Rd., South Yorkshire, S60 2UD, UK
D Bhalla
Affiliation:
Rotheham District General Hospital, UK
Get access Rights & Permissions [Opens in a new window]

Abstract

Two cases of prolonged hypersomnia following neuroleptic therapy are described. No previous reports exist in the literature. The implications are briefly discussed.

Keywords

Hypersomnianeurolepticsextrapyramidal symptoms
Type
Clinical & Brief Reports
Information
Irish Journal of Psychological Medicine , Volume 8 , Issue 2 , September 1991 , pp. 130 - 132
Copyright
Copyright © Cambridge University Press 1991

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Hollister, LE. Clinical pharmacology of psychotherapeutic drugs. New York: Churchill Livingstone, 1978.Google Scholar
2.McCreadie, RG, MacDonald, IM. High dose haloperidol in chronic schizophrenia. Br J Psychiatry 1977; 131: 310–316.CrossRefGoogle ScholarPubMed
3.Bjorndal, N, Bjerre, M, Gerlach, J, Kristjansen, P, Magilund, G, Oestrich, IJ, Waehrens, J. High dosage haloperidol therapy in chronic schizophrenic patients: a double blind study of clinical response, side effects, serum haloperidol and serum prolactin. Psychopharmacology 1980; 67: 17–23.CrossRefGoogle ScholarPubMed
4.Davis, JM, Organic therapies. In: Kaplan, HI, Sadock, BJ, editors. Comprehensive textbook of psychiatry vol II. Baltimore: Williams and Wilkins, 1985.Google Scholar
5.Seiden, LS, Dykstra, LA. Psychopharmacology: a biochemical and behavioural approach. New York: Nostrand Reinhold, 1977.Google Scholar
6.Marsden, CD, Jenner, P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 1980; 10: 55–72.CrossRefGoogle ScholarPubMed
7.Lishman, WA. Organic psychiatry. Oxford: Blackwell Scientific Publications, 1987.Google Scholar
8.Young, LY, Kimble, MAK. Applied therapeutics: the clinical use of drugs. Vancouver: Applied Therapeutics Inc, 1988.Google Scholar
9.Burrows, GD, Norman, TR. Psychotropic drugs: plasma concentrations and clinical response. Basel: Marcel Dekker Inc, 1981.Google Scholar
10.Goodman, LS, Gillman, AG. The pharmacological basis of therapeutics. London: Pergamon Press Inc, 1990.Google Scholar
11.Jorgensen, A, Overo, KF. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics (serum levels). Acta Psychiatr Scand 1980; 61 Suppl 279: 41–54.CrossRefGoogle Scholar
12.Reynolds, EF. Martindale, the extra pharmacopoeia. London: The Pharmaceutical Press, 1989.Google Scholar
13.Speight, MT. Avery's drug treatment: Principles and practice of clinical pharmacology and therapeutics. Aukland: Adis Press, 1987.Google Scholar
14.Gitlin, MJ. Middha, KK, Fogelson, D. J Clin Psychopharmacol 1988; 8: 53–56.CrossRefGoogle Scholar
15.Wistedt, B, Wiles, D, Kolakowska, T. Slow decline of plasma drug and prolactin levels after discontinuation of chronic treatment with depot neuroleptics. Lancet 1981; i: 1163.CrossRefGoogle Scholar
16.Waddington, JL, Gamble, SJ. Prolonged dopamine blockade in rats after termination of long-term depot fluphenazine. Lancet 1981; i: 1375–1376.CrossRefGoogle Scholar
17.Viala, A, Ba, B, Durand, A, Gouezo, F, Nhean, Hou, Jorgensen, A. Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate. Psychopharmacology 1988; 94: 293–297.CrossRefGoogle ScholarPubMed